ストックスクリーナーアプリを入手
83.55
3.47%
2.80
プレマーケット:
86.50
2.95
+3.53%
前日終値:
$80.75
開ける：
$80.63
24時間の取引高:
567.88K
Relative Volume:
0.60
時価総額：
$6.29B
収益：
-
当期純損益:
$-255.84M
株価収益率:
-19.82
EPS:
-4.2149
ネットキャッシュフロー:
$-232.60M
1週間 パフォーマンス:
-3.38%
1か月 パフォーマンス:
-0.94%
6か月 パフォーマンス:
+55.01%
1年 パフォーマンス:
+108.25%
1日の値動き範囲:
$80.52
$85.45
1週間の範囲:
$80.52
$87.69
52週間の値動き範囲:
$34.34
$95.31
Apogee Therapeutics Inc Stock (APGE) Company Profile
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
83.55 | 6.08B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
429.85 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.21 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.09 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.14 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Hold |
| 2026-01-22 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 開始されました | Wolfe Research | Peer Perform |
| 2025-12-17 | 開始されました | Stephens | Overweight |
| 2025-12-10 | 開始されました | Deutsche Bank | Buy |
| 2025-11-03 | 開始されました | Craig Hallum | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-09-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-07 | 繰り返されました | BTIG Research | Buy |
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-11-25 | 開始されました | Canaccord Genuity | Buy |
| 2024-05-10 | 開始されました | BofA Securities | Buy |
| 2023-12-20 | 開始されました | BTIG Research | Buy |
| 2023-08-08 | 開始されました | Guggenheim | Buy |
| 2023-08-08 | 開始されました | Jefferies | Buy |
| 2023-08-08 | 開始されました | Stifel | Buy |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
| 2023-08-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Apogee Therapeutics Inc (APGE) 最新ニュース
CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat
Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan
Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo
Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat
Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK
Rothschild Redburn initiates Apogee stock with buy on AD therapy By Investing.com - Investing.com India
Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics (APGE) Study result Summary - Quartr
Apogee Therapeutics (APGE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough - HarianBasis.co
Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters - Yahoo Finance
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Apogee Therapeutics, Inc. ($APGE) CEO 2025 Pay Revealed - Quiver Quantitative
Apogee Therapeutics Announces Upcoming Board Resignations, Governance Shift - TipRanks
Apogee Therapeutics (APGE) 2026 meeting to vote on directors, pay and auditor - Stock Titan
Two directors resign from Apogee Therapeutics (NASDAQ: APGE) board, shrinking it to seven - Stock Titan
Certain Common Stock of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Pre-Funded Warrants of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Restricted Stock Units of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Certain Stock Options of Apogee Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-APR-2026. - marketscreener.com
Apogee Thera (APGE) Stock Price Target | Q4 2025: Earnings Beat EstimatesTrending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
APGE (Apogee Therapeutics Inc.) posts narrower Q4 2025 loss than estimates, shares rise modestly after its latest quarterly earnings release.GDR - Cổng thông tin điện tử tỉnh Tây Ninh
APGE (Apogee Therapeutics Inc.) Q4 2025 EPS outpaces forecasts, shares gain as investors reward narrower than expected loss.Social Flow Trades - UBND thành phố Hải Phòng
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Apogee Therapeutics (APGE) CEO exercises options, holds 1.14M shares - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD By Investing.com - Investing.com India
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CFO Henderson sells $180,000 in stock - Investing.com
Apogee Therapeutics CFO Henderson sells $180,000 in stock By Investing.com - Investing.com India
Apogee Therapeutics (APGE) CFO sells 2,000 shares under 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 92.48 USD - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Apogee Therapeutics Inc (APGE) 財務データ
収益
当期純利益
現金流量
EPS
1.90%
大文字化:
|
ボリューム (24 時間):